MG
CYTK icon

Marex Group’s Cytokinetics CYTK Stock Holding History

Marex Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,301
Closed -$745K – 1190
2026
Q1 		$745K Buy
11,301
+3,299
+41% +$210K ﹤0.01% 515
2025
Q4 		$508K Buy
+8,002
New +$498K ﹤0.01% 561
2025
Q1 		– Sell
-31,500
Closed -$1.48M – 721
2024
Q4 		$1.48M Sell
31,500
-8,564
-21% -$445K 0.03% 191
2024
Q3 		$2.12M Buy
+40,064
New +$2.23M 0.05% 144

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group's CYTK Position: Q2 2026 in Review

Marex Group sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 11,301 shares — an estimated $745K sold.

Marex Group first reported a position in CYTK in Q3 2024 and held it in 4 quarters. The position peaked at $2.12M in Q3 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Marex Group reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Marex Group sold 11,301 Cytokinetics shares in Q2 2026, an estimated $745K.
  • Marex Group first reported a position in Cytokinetics in Q3 2024 and held it in 4 quarters.
  • Marex Group's Cytokinetics position peaked at $2.12M in Q3 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.